Previous close | 2.3300 |
Open | 2.3800 |
Bid | 0.4400 |
Ask | 3.9000 |
Strike | 74.00 |
Expiry date | 2024-05-03 |
Day's range | 2.3000 - 2.3800 |
Contract range | N/A |
Volume | |
Open interest | 141 |
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasda
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.